Latigo Biotherapeutics, Inc. (LTGO)Healthcare | Biotechnology | Thousand Oaks, United States | NasdaqGS
14.76 USD
+0.76
(5.429%)
⇧
(Oct. 15, 2026, 4 p.m.
EDT)
|
Hot Take ↕ | Oct. 10, 2026, 7:10 a.m. EDT
The immediate outlook is sharply negative as the stock has lost nearly 30% of its value over the last two weeks, crashing from highs near $21 to lows around $14.50. This violent sell-off, occurring while trading well below its 50-day average, suggests a complete loss of technical support and severe distribution pressure. Fundamentally, the business is in distress with negative earnings, negative operating cash flow, and a negative book value, indicating that the company is burning capital without generating value. The lack of any recent news headlines leaves investors exposed to uncertainty regarding the company's pipeline or financial runway. With no dividend to provide income and a balance sheet showing significant debt relative to equity, there is no margin of safety here. The statistical models offer no guidance due to insufficient data, confirming that this is a speculative vehicle with no predictable short-term pattern. Avoid this security entirely until there is clear evidence of a turnaround in both the clinical data and the financial statements. |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 249.96 |
| Market Cap | 978,578,368 |
| Forward P/E | -7.06 |
| Website | https://latigobio.com |
| Attribute | Value |
|---|---|
| 52 Week Change | -0.23287672 |
| Address1 | 1,300 Rancho Conejo Boulevard |
| Address2 | Suite 305 |
| All Time High | 25.93 |
| All Time Low | 13.85 |
| Ask | 14.84 |
| Ask Size | 5 |
| Average Analyst Rating | 1.0 - Strong Buy |
| Average Daily Volume10 Day | 323,900 |
| Average Daily Volume3 Month | 377,087 |
| Average Volume | 377,087 |
| Average Volume10Days | 323,900 |
| Bid | 14.69 |
| Bid Size | 6 |
| Book Value | -279.366 |
| City | Thousand Oaks |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 14.76 |
| Current Ratio | 1.148 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 14.9 |
| Day Low | 13.4975 |
| Debt To Equity | 249.96 |
| Display Name | Latigo Biotherapeutics |
| Dividend Yield | 0.0 |
| Earnings Timestamp End | 1,794,513,600 |
| Earnings Timestamp Start | 1,794,513,600 |
| Ebitda | -112,164,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -11.086 |
| Enterprise Value | 1,243,407,360 |
| Eps Forward | -2.09 |
| Eps Trailing Twelve Months | -2.25 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 19.995625 |
| Fifty Day Average Change | -5.2356243 |
| Fifty Day Average Change Percent | -0.2618385 |
| Fifty Two Week Change Percent | -23.287672 |
| Fifty Two Week High | 25.93 |
| Fifty Two Week High Change | -11.17 |
| Fifty Two Week High Change Percent | -0.43077517 |
| Fifty Two Week Low | 13.4975 |
| Fifty Two Week Low Change | 1.2624998 |
| Fifty Two Week Low Change Percent | 0.093535826 |
| Fifty Two Week Range | 13.4975 - 25.93 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,786,109,400,000 |
| Float Shares | 21,742,871 |
| Forward Eps | -2.09 |
| Forward P E | -7.0622015 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 66 |
| Fullday Change | 0.7600002 |
| Fullday Change Percent | 5.4519386 |
| Fullday Price | 14.76 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.04977 |
| Held Percent Institutions | 0.792 |
| Implied Shares Outstanding | 66,299,347 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,026-08-07 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Latigo Biotherapeutics, Inc. develops non-opioid pain medicines designed to stop the transmission of pain without the risk of addiction. The company's pipeline includes LTG-001, an oral NaV1.8 inhibitor designed to provide fast-acting, opioid-sparing relief for the treatment of acute pain; LTG-321, a NaV1.8 inhibitor candidate developed for the treatment of chronic musculoskeletal pain, starting with osteoarthritis; and LTG-418, a NaV1.8 inhibitor developed for the treatment of acute and chronic pain. Latigo Biotherapeutics, Inc. was formerly known as WVB-Desmond, Inc. and changed its name to Latigo Biotherapeutics, Inc. in March 2019. Latigo Biotherapeutics, Inc. was incorporated in 2018 and is based in Thousand Oaks, California. |
| Long Name | Latigo Biotherapeutics, Inc. |
| Market | us_market |
| Market Cap | 978,578,368 |
| Market State | POSTPOST |
| Max Age | 86,400 |
| Message Board Id | finmb_672821642 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -111,138,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 1,317,368,024 |
| Number Of Analyst Opinions | 4 |
| Open | 14.09 |
| Operating Cashflow | -103,191,000 |
| Operating Margins | 0.0 |
| Phone | 805 716 2927 |
| Previous Close | 14.0 |
| Price Hint | 2 |
| Price To Book | -0.05283392 |
| Profit Margins | 0.0 |
| Quick Ratio | 1.066 |
| Quote Source Name | Delayed Quote |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.0 |
| Region | US |
| Regular Market Change | 0.76 |
| Regular Market Change Percent | 5.42857 |
| Regular Market Day High | 14.9 |
| Regular Market Day Low | 13.4975 |
| Regular Market Day Range | 13.4975 - 14.9 |
| Regular Market Open | 14.09 |
| Regular Market Previous Close | 14.0 |
| Regular Market Price | 14.76 |
| Regular Market Time | 1,792,094,401 |
| Regular Market Volume | 242,898 |
| Sand P52 Week Change | 0.16440773 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 66,299,347 |
| Shares Percent Shares Out | 0.0126 |
| Shares Short | 832,088 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 308,625 |
| Short Name | Latigo Biotherapeutics, Inc. |
| Short Ratio | 2.26 |
| Source Interval | 15 |
| State | CA |
| Symbol | LTGO |
| Target High Price | 73.0 |
| Target Low Price | 36.0 |
| Target Mean Price | 52.25 |
| Target Median Price | 50.0 |
| Total Cash | 55,003,000 |
| Total Cash Per Share | 0.83 |
| Total Debt | 31,250,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -2.25 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 19.995625 |
| Two Hundred Day Average Change | -5.2356243 |
| Two Hundred Day Average Change Percent | -0.2618385 |
| Type Disp | Equity |
| Volume | 242,898 |
| Website | https://latigobio.com |
| Zip | 91,320 |